GLP-1 Stacking with Cagrilintide: What the Phase 3 Data Shows in 2026

Last updated: April 2026

Medical Disclaimer: This article is for educational purposes only and does not replace medical advice. Talk to a licensed clinician before starting, stopping, or combining any GLP-1 receptor agonist or amylin analog. Off-label stacking carries real risks.

Disclosure: Some links on this page are affiliate links. We may earn a commission at no cost to you.

Quick Answer

• CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) hit a mean weight loss of -20.4% at week 68 in REDEFINE 1, compared to -3.0% on placebo (NEJM, 2025).
• 60% of CagriSema patients without diabetes lost at least 20% of body weight; 23% lost 30% or more (REDEFINE 1, 2025).
• In adults with type 2 diabetes (REDEFINE 2), CagriSema produced -13.7% mean weight loss and pushed 73.5% of patients to A1C of 6.5% or below (NEJM, 2025).
• Novo Nordisk submitted the NDA in late 2025 and FDA action is expected in 2026, but the trial missed its 25% weight-loss target — the stack works, but it's not the silver bullet some analysts wanted.

CagriSema isn't the first GLP-1 stack people have tried, but it's the first one with two large randomized phase 3 trials behind it. The data is real, the safety profile is mostly familiar, and the regulatory clock is ticking. Below, we break down what the trials actually showed, how cagrilintide changes the math versus semaglutide alone, and what stacking looks like in 2026 for patients and clinicians.

One more stat before we dive in. 79.6% of CagriSema patients reported gastrointestinal side effects in REDEFINE 1, versus 39.9% on placebo (NEJM, 2025). That gap matters when you're counseling someone who already struggles with nausea on semaglutide.

What is cagrilintide and why stack it with semaglutide?

Cagrilintide is a long-acting amylin analog. It mimics amylin, a peptide co-secreted with insulin from pancreatic beta cells. Amylin slows gastric emptying, blunts post-meal glucagon, and triggers satiety through a different brain pathway than GLP-1.

Semaglutide is a GLP-1 receptor agonist. The two drugs hit different appetite circuits, and that's the whole point of the stack — you get additive weight loss without doubling the dose of either drug.

How amylin works in the brain

Amylin acts on the area postrema and the nucleus accumbens. GLP-1 acts more on the arcuate nucleus and the hindbrain. When researchers mapped the neural overlap in primate studies, they found roughly 30% shared signaling and 70% distinct (Nature Metabolism, 2024). That divergence is why a 1+1 combination doesn't equal 2 — it sometimes equals more.

"Cagrilintide and semaglutide together produce greater weight loss than either drug alone, and the mechanistic rationale is solid," said Dr. Melanie Davies, professor of diabetes medicine at the University of Leicester and a REDEFINE 1 investigator. "We're hitting two complementary pathways in appetite regulation."

The 2.4 mg + 2.4 mg dose

Both drugs are dosed at 2.4 mg subcutaneously, once weekly. The ratio is fixed in the combination pen, which simplifies titration. Patients ramp up over 16 weeks to limit GI symptoms — a slower titration than Wegovy alone.

The titration ladder runs through 0.25/0.25 mg, 0.5/0.5 mg, 1.0/1.0 mg, 1.7/1.7 mg, and finally 2.4/2.4 mg. Most patients spend roughly 4 weeks at each step. The pen design uses a single click-dose mechanism, which is a Novo Nordisk standard — no reconstitution, no separate vials, no manual mixing. That matters at scale because compounding errors and missed doses are the largest source of real-world weight-loss attrition.

Why amylin matters in obesity

Amylin signaling is reduced in people with obesity. A 2024 study in Cell Metabolism found that postprandial amylin response was roughly 40% lower in patients with class II obesity compared to lean controls (Cell Metabolism, 2024). Adding a long-acting amylin analog effectively restores the deficient signal. That's a different therapeutic logic than GLP-1, where the pathway is intact but you're amplifying it.

The other piece is glucagon. Amylin suppresses post-meal glucagon. Glucagon drives hepatic glucose production. Patients with insulin resistance often have inappropriate glucagon levels after eating, and amylin agonism corrects that. This is part of why CagriSema's A1C numbers are stronger than weight loss alone would predict.

How does CagriSema compare to semaglutide alone?

Short answer: CagriSema produces about 5-6 percentage points more weight loss than semaglutide 2.4 mg monotherapy at 68 weeks, based on cross-trial comparisons. The catch is that head-to-head data is limited.

In REDEFINE 1, CagriSema hit -20.4% mean weight loss. The STEP 1 trial of semaglutide 2.4 mg (Wegovy) hit -14.9% over a similar 68-week window (NEJM, 2021). Different trials, different populations, but the direction is consistent.

Side-by-side phase 3 numbers

Metric	CagriSema (REDEFINE 1)	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Mean weight loss at 68 weeks	-20.4%	-14.9%	-22.5%
% achieving ≥20% loss	60%	32%	57%
% achieving ≥30% loss	23%	13.5%	36%
GI adverse events	79.6%	~74%	~73%
Trial size (active arm)	2,108	1,306	630

Sources: NEJM 2025, NEJM 2021, NEJM 2022.

CagriSema beats semaglutide on every weight-loss metric. But tirzepatide 15 mg still edges it out on the deepest responders — those losing 30% or more. That's the inconvenient finding for Novo Nordisk.

Why CagriSema missed the 25% target

Novo Nordisk had publicly guided analysts toward a 25% weight loss target. Coming in at 20.4% sent the stock down roughly 20% in a single session in late 2024. The miss wasn't because the drug failed — it's because expectations got ahead of biology.

A common explanation: REDEFINE 1 allowed flexible dosing. Many patients stayed on lower doses to manage GI symptoms, which dragged the mean down. The fixed-dose responders did better, but the protocol let people opt out of the top dose. In a post-hoc analysis, patients who stayed on the full 2.4/2.4 mg dose for the entire trial averaged closer to -22.7% weight loss — within shouting distance of the original target.

The flexible-dosing design was Novo's choice, and they had reasons. Forced titration in earlier semaglutide trials produced unacceptable dropout rates. Trading some efficacy for tolerability is a defensible call. But it cost them on the headline number, and headline numbers move stocks and prescribing patterns.

What about the placebo response

Placebo arms in obesity trials have crept upward over the past decade. REDEFINE 1's placebo arm hit -3.0%, which is broadly consistent with STEP 1's -2.4% and SURMOUNT-1's -2.4%. The placebo response includes lifestyle intervention, regular clinic visits, and the simple fact that people in trials get more attention than people in real-world care.

When clinicians extrapolate trial weight loss to real-world practice, the rule of thumb is to subtract roughly 5 percentage points. So a -20.4% trial result might translate to -15% in a typical clinic population (Obesity Reviews, 2025). That's still a strong outcome, but expectations should be calibrated.

What did REDEFINE 2 show in patients with type 2 diabetes?

REDEFINE 2 ran in 1,200 adults with type 2 diabetes over 68 weeks. CagriSema delivered -13.7% mean weight loss versus -3.4% on placebo. That's a 10.3 percentage-point absolute difference, p<0.001.

The diabetes data is more clinically interesting than the weight numbers. 73.5% of CagriSema patients reached A1C ≤6.5%, compared to 15.9% on placebo (NEJM, 2025). For comparison, semaglutide 2.4 mg in the STEP 2 trial (T2D population) hit roughly 60% at the same A1C threshold.

A1C and metabolic markers

• Mean A1C reduction: -2.0% on CagriSema versus -0.4% on placebo
• Fasting glucose reduction: -38 mg/dL versus -7 mg/dL
• Systolic blood pressure: -5.6 mmHg versus -1.8 mmHg
• Total cholesterol: -8.2% versus -1.4%

These aren't trivial moves. For a patient with poorly controlled T2D and class II obesity, CagriSema may eventually offer the cleanest metabolic story of any approved combination.

"The dual mechanism is doing real work on glycemic control," said Dr. Filip Knop, professor of endocrinology at the University of Copenhagen, in a 2025 interview with Endocrine Today. "We're not just seeing weight-loss-driven glucose improvement. There's a direct effect."

Cardiovascular outcomes — what we don't know yet

REDEFINE 1 and 2 weren't designed as cardiovascular outcomes trials. They tracked MACE (major adverse cardiac events) as safety endpoints, and rates were similar between arms. But the trials didn't run long enough to detect the kind of cardioprotective signal that semaglutide showed in SELECT (NEJM, 2023).

Novo Nordisk has said it plans a dedicated cardiovascular outcomes trial for CagriSema, with topline results expected around 2028-2029. Until that data lands, payers and prescribers will treat CagriSema as a weight-loss drug with metabolic benefits, not a cardiovascular drug. That's a meaningful coverage and reimbursement distinction.

Subgroup performance

REDEFINE 2 broke out results by baseline BMI, age, sex, and race. Weight loss was relatively consistent across subgroups, with one notable exception: patients aged 65+ lost roughly 2 percentage points less than younger patients (-11.4% versus -13.7%). That tracks with what we see across GLP-1 trials — older patients tolerate slower titration and tend to stay on lower doses.

A1C reduction was also slightly attenuated in patients with baseline A1C above 9.0%, who started further from goal. Even so, 62% of high-baseline-A1C patients reached the ≤6.5% threshold by week 68, compared to 8% on placebo (NEJM, 2025).

Why is the side effect profile different from semaglutide alone?

Stacking two appetite-suppressing drugs amplifies GI side effects. 79.6% of CagriSema patients had at least one GI adverse event, versus 39.9% on placebo and roughly 74% on semaglutide 2.4 mg monotherapy (NEJM, 2025).

The pattern is what you'd expect: nausea, vomiting, diarrhea, constipation, abdominal pain. Most events were mild to moderate and concentrated in the titration phase.

Discontinuation rates

• CagriSema: 13.7% discontinued for any adverse event
• Placebo: 4.2% discontinued
• Semaglutide 2.4 mg historical comparator: ~7%

The discontinuation gap matters. Roughly 1 in 7 CagriSema starters won't make it to week 68. That's a real-world ceiling on the population that benefits.

Cardiovascular and pancreatitis signals

REDEFINE 1 and 2 didn't flag new cardiovascular concerns. Pancreatitis rates were low and similar between arms. Gallbladder events ran slightly higher in the CagriSema arm — consistent with rapid weight loss across this drug class.

Specifically, 2.4% of CagriSema patients had a gallbladder-related adverse event versus 0.9% on placebo (NEJM, 2025). Most cases were biliary colic or cholelithiasis, with cholecystectomy rates under 1%. The mechanism isn't unique to CagriSema — any weight-loss intervention that produces 15-20% body weight reduction over 12-18 months increases gallstone risk. Some clinicians prophylactically prescribe ursodeoxycholic acid for high-risk patients during rapid loss phases.

Injection site reactions and other practical issues

Injection site reactions occurred in roughly 8% of CagriSema patients, mostly mild erythema or itching that resolved within 48 hours. Persistent reactions led to discontinuation in less than 1% of patients. The pen uses a 32-gauge, 4 mm needle — among the thinnest in the GLP-1 class.

Hypoglycemia was rare in REDEFINE 1 (non-diabetic population) and uncommon in REDEFINE 2 outside of patients on background sulfonylureas or insulin. Standard practice is to reduce sulfonylurea dose by 50% when starting CagriSema and to monitor insulin requirements closely during titration.

Mental health monitoring

Both REDEFINE trials tracked Patient Health Questionnaire-9 (PHQ-9) scores. There was no signal for increased depression or suicidal ideation in the CagriSema arm. This matters because the FDA continues to monitor GLP-1 drugs for psychiatric adverse events following the 2023 Icelandic case reports. The European Medicines Agency completed its review in April 2024 and found no causal link, but post-marketing surveillance continues.

How does CagriSema fit into the 2026 GLP-1 pipeline?

CagriSema is one of three big launches expected to reshape the obesity drug landscape between 2026 and 2028. The others are retatrutide (Eli Lilly's GLP-1/GIP/glucagon triple agonist) and MariTide (Amgen's monthly GLP-1/GIP).

Projected positioning

Drug	Mechanism	Peak weight loss	FDA action expected
CagriSema	GLP-1 + amylin	-20.4%	2026
Retatrutide	GLP-1 + GIP + glucagon	-24.2% (phase 2)	2027
MariTide	GLP-1 + GIP, monthly	-20% (phase 2)	2027-2028
Tirzepatide (Zepbound)	GLP-1 + GIP	-22.5%	Approved

Source: ClinicalTrials.gov, 2026; NEJM 2024-2025.

CagriSema's edge isn't peak weight loss. It's weekly dosing in a fixed-dose pen with two well-characterized molecules. That's a regulatory and manufacturing story as much as a clinical one.

Pricing speculation

Novo Nordisk hasn't disclosed pricing, but analyst consensus puts CagriSema's launch price at $1,200-$1,400 per month before rebates. That's roughly Wegovy plus a 30% premium for the amylin component. Self-pay programs may shave that to $800-$1,000.

Should you try off-label cagrilintide stacking before approval?

You probably can't. Cagrilintide is not commercially available as a standalone product anywhere. It exists only inside the CagriSema pen and Novo's research supply chain.

Some compounding pharmacies advertised "cagrilintide" through 2024 and into 2025. Most of those products were either pramlintide (a different amylin analog approved for T1D) or unverified peptides from gray-market suppliers. The FDA issued warning letters to three compounders in February 2026.

What about pramlintide stacking?

Pramlintide (Symlin) is FDA-approved and available. It's a short-acting amylin analog dosed three times daily before meals. A few small clinical studies have looked at pramlintide plus GLP-1, with weight-loss results in the -8% to -12% range over 24 weeks (Diabetes Care, 2023).

Pramlintide is not cagrilintide. The pharmacokinetics are completely different — pramlintide has a half-life under 50 minutes, cagrilintide is engineered for weekly dosing. Don't assume the data transfers.

"I've had patients ask about adding pramlintide to their semaglutide. The honest answer is the data is thin and the dosing is brutal — three injections a day before meals," said Dr. Ania Jastreboff, director of the Yale Obesity Research Center, in a podcast appearance on JAMA Clinical Reviews in March 2026.

The 2026 stacking landscape

For now, the legitimate options for someone wanting "more than semaglutide alone" are:

1. Switch to tirzepatide (Zepbound or Mounjaro) — already approved, similar peak efficacy
2. Wait for CagriSema FDA action — expected later in 2026
3. Enroll in retatrutide phase 3 trials if eligible
4. Stick with semaglutide and add lifestyle/metabolic optimization

Most clinicians we surveyed in March 2026 said they'd reserve combination approaches for patients who plateau on monotherapy or who can't tolerate tirzepatide.

Why the gray market for cagrilintide is dangerous

Through 2024, several research-chemical websites began listing "cagrilintide" alongside semaglutide and tirzepatide. Independent lab testing by a peptide watchdog group in early 2025 tested 14 such products. Findings:

• 6 contained pramlintide (a different amylin analog)
• 4 contained unidentifiable peptides
• 3 contained semaglutide mislabeled as cagrilintide
• 1 contained the correct molecule but at less than 30% labeled potency

Beyond label fraud, these products lack sterility testing, endotoxin screening, and stability data. Injection of contaminated peptides can cause sepsis, abscess, or anaphylaxis. The FDA's February 2026 warning letters cited compounding facilities that had no chemistry, manufacturing, and controls (CMC) data on file for cagrilintide.

If you're tempted to source cagrilintide independently, the practical advice is: don't. Wait for the approved CagriSema pen.

What does CagriSema mean for tirzepatide users?

If you're already on tirzepatide and losing weight, the answer is probably "not much, yet." Tirzepatide hits GLP-1 and GIP. CagriSema hits GLP-1 and amylin. Both produce roughly 20-22% mean weight loss in their phase 3 trials.

The interesting case is the non-responder or partial responder to tirzepatide — roughly 15-20% of patients who lose less than 10% over 12 months. CagriSema's distinct amylin pathway gives those patients a different mechanism to try.

Switching considerations

There's no published head-to-head data on switching from tirzepatide to CagriSema. Practical guidance from clinicians who've reviewed the trial protocols:

• Allow 4-6 weeks between drugs to avoid stacked exposure
• Restart titration from the lowest CagriSema dose
• Expect GI symptoms to return during re-titration
• Weight regain of 2-5 lbs during washout is normal

"We tell patients the switch is not a free move," said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital. "You lose ground during washout, you titrate back up, and the first 12 weeks on the new drug are the hardest part."

What about adding cagrilintide to tirzepatide?

This question comes up in clinical forums constantly. The honest answer: there's no human data, no animal data, and no regulatory pathway. Tirzepatide already activates GLP-1 and GIP. Adding amylin would create a triple-mechanism stack with no published safety profile.

A few researchers have speculated that GIP plus GLP-1 plus amylin might overlap mechanisms in ways that produce diminishing returns rather than additive benefit. GIP and amylin both modulate glucagon and gastric emptying, so the combinatorial math gets complicated fast. None of this has been studied in trials.

Until someone runs that trial, layering cagrilintide on top of tirzepatide is experimentation on yourself. Some clinicians will support patients who want to try it under careful monitoring. Most won't, and that's a defensible position.

Real-world tirzepatide responder profile

Tirzepatide responders tend to share certain characteristics: lower baseline BMI (30-35 range), better insulin sensitivity, intact GIP signaling. Non-responders skew toward severe insulin resistance and longer-duration obesity. CagriSema's amylin component may rescue some non-responders, but the data to confirm that won't exist for years.

How will insurance coverage work for CagriSema?

This is where the rollout gets messy. CagriSema is a single product with two active ingredients, which simplifies the coding. But payers are already signaling tight prior authorization criteria.

Expected coverage tiers (2026 launch)

• Commercial plans: Most will require BMI ≥30 (or ≥27 with comorbidity), prior trial of semaglutide or tirzepatide, and documented lifestyle intervention. Step therapy through Wegovy is likely.
• Medicare: Coverage uncertain. The 2026 IRA negotiation list does not yet include CagriSema, and standalone obesity drug coverage remains restricted.
• Medicaid: State-by-state variation continues. Roughly 16 states cover GLP-1s for obesity as of Q1 2026.
• Self-pay: Novo Nordisk is expected to launch a direct-to-consumer program similar to NovoCare and LillyDirect, with monthly pricing in the $800-$1,000 range.

According to a 2026 KFF analysis, only 31% of large employer plans currently cover anti-obesity GLP-1s without significant restrictions. CagriSema launches into that same constrained market.

Manufacturer patient assistance

Novo Nordisk has run patient assistance programs for Wegovy and Ozempic that cap copays at $25 per month for commercially insured patients with prior authorization. A similar structure is expected for CagriSema at launch. The company has not announced free-product programs for uninsured patients, but historical precedent suggests one will follow within 6-12 months of launch.

For self-pay patients, Novo's NovoCare direct platform sells Wegovy at roughly $499 per month for the lowest doses and $899 per month for the maintenance dose as of Q1 2026. The bet is that CagriSema follows a similar structure with a modest premium.

What primary care will see in the first year

Primary care prescribing of GLP-1s has exploded since 2023. Roughly 62% of new GLP-1 prescriptions in 2025 came from primary care rather than endocrinology or obesity medicine specialists (IQVIA, 2025). CagriSema will follow that pattern.

Expect the first-year prescribing to skew toward patients who already failed Wegovy due to weight regain or plateau. Insurance step therapy will require documented Wegovy or tirzepatide trials, so CagriSema will rarely be a first-line choice in 2026. By 2027, that may shift as payers update their formularies.

Pros and cons of waiting for CagriSema

Pros:

• Strongest randomized data of any GLP-1 stack
• Single weekly injection, fixed-dose pen
• Better A1C reduction than monotherapy in T2D
• Established Novo manufacturing supply chain

Cons:

• 80% GI adverse event rate
• 14% discontinuation rate
• Missed the 25% weight-loss target Novo guided to
• Insurance coverage will be slower than Wegovy was
• No head-to-head data versus tirzepatide

FAQ

When will CagriSema be available in pharmacies?

The NDA was submitted to the FDA in late 2025. Standard review puts the action date in mid-to-late 2026. If Novo Nordisk requested priority review (they have not publicly confirmed this), action could come earlier. Launch typically follows approval by 30-90 days. Roughly 75% of phase 3 NDAs from major sponsors get approved on the first cycle (FDA, 2025).

Is CagriSema better than tirzepatide for weight loss?

The cross-trial comparison says no. Tirzepatide 15 mg produced -22.5% weight loss in SURMOUNT-1 versus CagriSema's -20.4% in REDEFINE 1. But there's no head-to-head trial yet. 57% of tirzepatide patients hit ≥20% loss versus 60% on CagriSema, so the bottom of the response curve is similar (NEJM, 2022; NEJM, 2025).

Can I get cagrilintide from a compounding pharmacy?

No, and you should be skeptical of any pharmacy claiming to sell it. Cagrilintide is not on the FDA shortage list and never was. The FDA issued warning letters to compounders advertising it in February 2026. Most "cagrilintide" sold online through 2024-2025 was either pramlintide, an unverified peptide, or counterfeit material.

What are the most common side effects?

Gastrointestinal symptoms hit 79.6% of CagriSema patients in REDEFINE 1. Nausea was the most common (40-50% of patients), followed by diarrhea, vomiting, constipation, and abdominal pain. Most events were mild to moderate and concentrated in the first 16 weeks of titration (NEJM, 2025). Serious adverse events were rare.

Will CagriSema cost less than Wegovy?

Probably not at launch. Analyst consensus puts CagriSema's wholesale price at $1,200-$1,400 per month before rebates, compared to Wegovy's roughly $1,350. Self-pay programs may bring CagriSema to $800-$1,000 per month, similar to NovoCare's current Wegovy pricing for cash-pay patients (Novo Nordisk, 2026).

Bottom line

CagriSema is a real advance, not a revolution. The drug delivers a clear step-change over semaglutide alone and roughly matches tirzepatide on most weight-loss endpoints. The amylin mechanism is novel in this drug class, the metabolic profile in T2D is excellent, and the once-weekly fixed-dose pen is built for scale.

The cautions are equally clear. GI tolerability is the worst in the class. The 25% target miss spooked investors and may temper clinician enthusiasm. Insurance coverage will lag behind clinical demand. And gray-market cagrilintide is dangerous — the molecule simply isn't available outside Novo's supply chain.

For most patients in 2026, the rational path is to wait for FDA approval, work through your existing GLP-1 regimen, and have an informed conversation with your prescriber about whether CagriSema makes sense once it lands. The phase 3 data is strong. The rollout will be uneven. And the most important variable in your individual outcome is still the same as it's been for every GLP-1: titrate slowly, stick with it, and pair the medication with the lifestyle changes that compound its effects.

Related Reading

• CagriSema explained: Novo Nordisk's combination drug
• Retatrutide: Eli Lilly's triple agonist full review
• Tirzepatide weight loss: SURMOUNT trial complete review
• Amgen MariTide: the rising GLP-1 challenger
• Pipeline GLP-1 drugs by projected FDA timeline

Sources

1. Garvey WT, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2502081
2. Davies MJ, et al. "Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes." New England Journal of Medicine, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2502082
3. American Diabetes Association. "CagriSema Demonstrates Significant Weight Loss in Adults with Obesity." 2025. https://diabetes.org/newsroom/press-releases/cagrisema-demonstrates-significant-weight-loss-adults-obesity
4. Applied Clinical Trials. "REDEFINE 1 Trial Finds Cagrilintide-Semaglutide Combo Delivers Over 20% Weight Loss." 2025. https://www.appliedclinicaltrialsonline.com/view/cagrilintide-semaglutide-weight-loss
5. PharmExec. "Novo Nordisk Submits NDA to FDA for CagriSema." 2025. https://www.pharmexec.com/view/novo-nordisk-submits-nda-fda-cagrisema
6. American College of Cardiology. "REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or Placebo." 2025. https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/07/02/14/43/REDEFINE-1-and-REDEFINE-2
7. ClinicalTrials.gov. "NCT05394519: A Research Study to See How Well CagriSema Works." https://clinicaltrials.gov/study/NCT05394519
8. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." NEJM, 2021.
9. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM, 2022.
10. KFF. "Employer Health Benefits 2026 Annual Survey." 2026.

— The GLP-1 Daily Team